|
Gene: MUL1 |
Gene summary for MUL1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | MUL1 | Gene ID | 79594 |
Gene name | mitochondrial E3 ubiquitin protein ligase 1 | |
Gene Alias | C1orf166 | |
Cytomap | 1p36.12 | |
Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | A0A024RAA0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79594 | MUL1 | LZE4T | Human | Esophagus | ESCC | 2.04e-03 | 7.46e-02 | 0.0811 |
79594 | MUL1 | LZE8T | Human | Esophagus | ESCC | 2.95e-04 | 1.00e-01 | 0.067 |
79594 | MUL1 | LZE20T | Human | Esophagus | ESCC | 1.99e-03 | 1.08e-01 | 0.0662 |
79594 | MUL1 | LZE24T | Human | Esophagus | ESCC | 1.28e-02 | 1.65e-01 | 0.0596 |
79594 | MUL1 | LZE6T | Human | Esophagus | ESCC | 2.80e-03 | 2.44e-01 | 0.0845 |
79594 | MUL1 | P1T-E | Human | Esophagus | ESCC | 1.84e-02 | 1.17e-01 | 0.0875 |
79594 | MUL1 | P2T-E | Human | Esophagus | ESCC | 7.39e-28 | 3.33e-01 | 0.1177 |
79594 | MUL1 | P4T-E | Human | Esophagus | ESCC | 4.33e-10 | 1.29e-01 | 0.1323 |
79594 | MUL1 | P5T-E | Human | Esophagus | ESCC | 6.41e-09 | 7.27e-02 | 0.1327 |
79594 | MUL1 | P8T-E | Human | Esophagus | ESCC | 5.45e-12 | 1.38e-01 | 0.0889 |
79594 | MUL1 | P9T-E | Human | Esophagus | ESCC | 2.98e-05 | 9.54e-02 | 0.1131 |
79594 | MUL1 | P10T-E | Human | Esophagus | ESCC | 1.09e-16 | 2.28e-01 | 0.116 |
79594 | MUL1 | P11T-E | Human | Esophagus | ESCC | 7.86e-12 | 5.18e-01 | 0.1426 |
79594 | MUL1 | P12T-E | Human | Esophagus | ESCC | 1.54e-15 | 1.72e-01 | 0.1122 |
79594 | MUL1 | P15T-E | Human | Esophagus | ESCC | 2.95e-16 | 2.69e-01 | 0.1149 |
79594 | MUL1 | P16T-E | Human | Esophagus | ESCC | 9.89e-20 | 2.22e-01 | 0.1153 |
79594 | MUL1 | P17T-E | Human | Esophagus | ESCC | 7.43e-05 | 2.33e-01 | 0.1278 |
79594 | MUL1 | P19T-E | Human | Esophagus | ESCC | 2.91e-06 | 4.78e-01 | 0.1662 |
79594 | MUL1 | P20T-E | Human | Esophagus | ESCC | 6.23e-09 | 1.29e-01 | 0.1124 |
79594 | MUL1 | P21T-E | Human | Esophagus | ESCC | 7.12e-25 | 4.51e-01 | 0.1617 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0031647111 | Esophagus | ESCC | regulation of protein stability | 223/8552 | 298/18723 | 5.76e-25 | 1.52e-22 | 223 |
GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
GO:1903320111 | Esophagus | ESCC | regulation of protein modification by small protein conjugation or removal | 181/8552 | 242/18723 | 1.80e-20 | 2.60e-18 | 181 |
GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
GO:0045862111 | Esophagus | ESCC | positive regulation of proteolysis | 256/8552 | 372/18723 | 7.88e-20 | 9.43e-18 | 256 |
GO:0006839110 | Esophagus | ESCC | mitochondrial transport | 187/8552 | 254/18723 | 8.35e-20 | 9.81e-18 | 187 |
GO:000020917 | Esophagus | ESCC | protein polyubiquitination | 170/8552 | 236/18723 | 1.40e-16 | 1.09e-14 | 170 |
GO:0050821111 | Esophagus | ESCC | protein stabilization | 140/8552 | 191/18723 | 6.50e-15 | 3.61e-13 | 140 |
GO:000700619 | Esophagus | ESCC | mitochondrial membrane organization | 93/8552 | 116/18723 | 2.16e-14 | 1.11e-12 | 93 |
GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
GO:190300816 | Esophagus | ESCC | organelle disassembly | 89/8552 | 114/18723 | 1.36e-12 | 5.80e-11 | 89 |
GO:004312318 | Esophagus | ESCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 132/8552 | 186/18723 | 2.07e-12 | 8.58e-11 | 132 |
GO:0010821110 | Esophagus | ESCC | regulation of mitochondrion organization | 107/8552 | 144/18723 | 2.31e-12 | 9.41e-11 | 107 |
GO:0043122110 | Esophagus | ESCC | regulation of I-kappaB kinase/NF-kappaB signaling | 167/8552 | 249/18723 | 6.11e-12 | 2.32e-10 | 167 |
GO:0008637110 | Esophagus | ESCC | apoptotic mitochondrial changes | 83/8552 | 107/18723 | 1.43e-11 | 5.08e-10 | 83 |
GO:2000116111 | Esophagus | ESCC | regulation of cysteine-type endopeptidase activity | 158/8552 | 235/18723 | 1.67e-11 | 5.90e-10 | 158 |
GO:0043281111 | Esophagus | ESCC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 143/8552 | 209/18723 | 2.12e-11 | 7.31e-10 | 143 |
GO:000724919 | Esophagus | ESCC | I-kappaB kinase/NF-kappaB signaling | 183/8552 | 281/18723 | 3.02e-11 | 1.01e-09 | 183 |
GO:0016049110 | Esophagus | ESCC | cell growth | 289/8552 | 482/18723 | 1.29e-10 | 3.77e-09 | 289 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MUL1 | SNV | Missense_Mutation | c.314N>A | p.Arg105Gln | p.R105Q | Q969V5 | protein_coding | tolerated(0.13) | probably_damaging(0.998) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
MUL1 | SNV | Missense_Mutation | rs758966256 | c.532C>T | p.Arg178Trp | p.R178W | Q969V5 | protein_coding | deleterious(0) | probably_damaging(0.92) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
MUL1 | SNV | Missense_Mutation | novel | c.471G>T | p.Glu157Asp | p.E157D | Q969V5 | protein_coding | deleterious(0.01) | possibly_damaging(0.506) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
MUL1 | SNV | Missense_Mutation | rs773923328 | c.146A>C | p.Glu49Ala | p.E49A | Q969V5 | protein_coding | tolerated(0.57) | benign(0.026) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
MUL1 | SNV | Missense_Mutation | novel | c.421N>A | p.Val141Met | p.V141M | Q969V5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MUL1 | SNV | Missense_Mutation | novel | c.511N>A | p.Gly171Ser | p.G171S | Q969V5 | protein_coding | tolerated(0.12) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MUL1 | SNV | Missense_Mutation | c.758N>T | p.Ala253Val | p.A253V | Q969V5 | protein_coding | tolerated(0.08) | benign(0.005) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MUL1 | SNV | Missense_Mutation | novel | c.806G>A | p.Arg269His | p.R269H | Q969V5 | protein_coding | deleterious(0) | possibly_damaging(0.7) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
MUL1 | SNV | Missense_Mutation | c.419G>A | p.Arg140Gln | p.R140Q | Q969V5 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
MUL1 | SNV | Missense_Mutation | novel | c.907N>T | p.Val303Leu | p.V303L | Q969V5 | protein_coding | deleterious(0.01) | benign(0.192) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |